Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;75(6):1566-1578.
doi: 10.1002/hep.32265. Epub 2021 Dec 19.

The impact of hepatitis B vaccination in the United States, 1999-2018

Wen-Qiang He  1 , Guan Nan Guo  1   2 , Chenxi Li  1
Affiliations

The impact of hepatitis B vaccination in the United States, 1999-2018

Wen-Qiang He et al. Hepatology. 2022 Jun.

Abstract

Background and aims: Hepatitis B vaccine has been included in the infant immunization schedule since 1991 in the United States. We aimed to assess its effectiveness against HBV infection and its impact on mortality.

Approach and results: The study population was participants aged 6+ years with an HBV vaccination history and an HBV serologic test from the National Health and Nutrition Examination Survey, 1999-2018. Participants aged 18+ years with linked mortality records from 1999-2014 were followed for mortality analysis. Multivariable logistic regression was used to compute vaccine effectiveness (VE) overall, by year of birth, and by age. Cox regression was used to estimate HRs for all-cause, cancer-related, and cardiovascular disease-related mortality. A total of 64,107 participants were included in the main analysis, with 29,600 (40.7%) having completed HBV vaccination (three or more doses, vaccinated). The highest vaccination uptake was found among those born after 1991, at 86.5%. Vaccinated participants had higher prevalence of vaccine-induced immunity than the unvaccinated (47.2% vs. 7.4%). Among those born after 1991, VE was found at 58% (95% CI, 18%-79%) overall and 85% for those aged ≥20 years (mean age, 22), whereas no effect was found among those born prior to 1990. HBV vaccination was associated with reduced risk of all-cause mortality (HR, 0.78; 95% CI, 0.68-0.90) and cancer-related mortality (HR, 0.76; 95% CI, 0.58-1.00) but not for cardiovascular disease-related mortality.

Conclusions: In the universal infant vaccination era, the HBV vaccine has shown substantial effectiveness against HBV infection and maintained strong protection for 20 years. It was also associated with reduced risk of all-cause and cancer-related mortality.

PubMed Disclaimer

Comment in

References

    1. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd‐Allah F, Abdel‐Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life‐years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5:1749–68.
    1. Roberts H, Ly KN, Yin S, Hughes E, Teshale E, Jiles R. Prevalence of HBV infection, vaccine‐induced immunity, and susceptibility among at‐risk populations: US households, 2013–2018. Hepatology. 2021;74:2353–65.
    1. Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011–2016. Clin Infect Dis. 2019;69:709–12.
    1. World Health Organization . Hepatitis B. https://www.who.int/news‐room/fact‐sheets/detail/hepatitis‐b (2021). Accessed 11 Sept 2021.
    1. Abara WE, Collier MG, Teshale EH. Impact of universal infant hepatitis B vaccination in the US‐affiliated Pacific Islands, 1985–2015. Vaccine. 2017;35:997–1000.

Substances